logo image
search icon
date background image

Jul 10, 2024

The peptide CDMO (Pharmaceutical) market is about to explode with growth: New report provides that the market will reach $4,784.50 million by 2031.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Peptide CDMO (Pharmaceutical) Market Size, Share & Trends Analysis Report By Scale of Operation (Preclinical / Clinical, Commercial), By Method Used, (Chemical Synthesis Method, Non-Chemical Synthesis Method), By Applications (Peptide Supplements, Peptide Vaccines, Peptides as Radio-Theranostic Agents, Cell Penetrating Peptides (CPPs), Affinity Ligands, Protein Mimics), By Synthesis Types (LPPS, SPPS, Mixed Phase)- Market Outlook And Industry Analysis 2031"


The Global Peptide CDMO (Pharmaceutical) Market is valued at US$ 2,341.67 Mn in 2023, and it is expected to reach US$ 4,784.50 Mn by 2031, with a CAGR of 9.5% during the forecast period of 2024-2031.


Request Complete FREE Sample Report Click Here: https://www.insightaceanalytic.com/request-sample/1202


Peptides, composed of amino acids linked by peptide bonds, are essential molecules in biology with diverse applications in medicine. They offer high specificity and safety, making them ideal for targeted therapies for various diseases like oncology, diabetes, and cardiovascular disorders. This versatility has spurred their prominence as valuable tools in drug development.


Peptide Contract Development and Manufacturing Organizations (CDMOs) specialize in supporting pharmaceutical companies through the complex journey of peptide drug development. These firms provide a range of critical services, including synthesis, purification, isolation, and analytical testing, leveraging advanced technologies to ensure efficiency and quality. By partnering with peptide CDMOs, pharmaceutical companies gain access to specialized expertise and infrastructure, facilitating faster development timelines and streamlined manufacturing processes. This collaboration plays a pivotal role in bringing innovative peptide-based therapies from the lab to clinical application, advancing healthcare through targeted and effective treatment options.


List of Prominent Players in the Peptide CDMO (Pharmaceutical) Market:

  • AmbioPharm
  • Auspep
  • Bachem
  • BCN Peptide
  • CPC Scientific
  • CBL- Chemical and Biopharmaceutical Laboratories
  • Creative Peptides
  • Chinese Peptide
  • CSBio
  • Corden Pharma
  • PolyPeptide
  • Hybio Pharmaceutical
  • Peptide Institute
  • Pepscan
  • Almac
  • Vivitide
  • CreoSalus Inc
  • ScinoPharm
  • Senn Chemicals
  • Wuxi AppTec
  • Olon
  • Belyntic
  • Ferring Pharma
  • Numaferm
  • Hybio Pharmaceutical
  • Provepharm Life Solutions
  • Enzene Biosciences
  • Ardena Holding
  • Stelis Biopharma
  • Piramal Pharma
  • Space Peptides Pharmaceutical


Market Dynamics:


The increasing clinical applications of peptides across diverse therapeutic areas, including oncology, diabetes, and cardiovascular diseases, are driving significant demand for peptide-based drugs. Technological advancements supporting improved development and manufacturing of these therapies are bolstering market growth. Pharmaceutical companies are increasingly investing in peptide therapies to address unmet medical needs, with the industry investing over €42,500 million in R&D in Europe alone in 2021, according to EFPIA (The European Federation of Pharmaceutical Industries and Associations). Moreover, the growing prevalence of chronic diseases worldwide, such as cancer and diabetes, underscores the urgent need for effective peptide-based treatments, further fueling demand for services provided by peptide Contract Development and Manufacturing Organizations (CDMOs).



The peptide CDMO market faces challenges such as high outsourcing costs, intense competition among established players, and the rapid evolution of technology. These factors require continuous investment in R&D to remain competitive and address budget constraints that may limit market growth.


Regional Trends:

The United States stands as the largest market for peptide and oligonucleotide CDMO services, driven by its extensive pharmaceutical and biotechnology sector. Pharmaceutical companies in the U.S. favor outsourcing their manufacturing needs to U.S.-based CROs due to their proven track record in delivering high-quality peptide and oligonucleotide products and services. The region's substantial investment in R&D activities, with pharmaceutical companies alone investing over $102 billion in 2021, underscores the robust growth of the peptide CDMO market in North America. This environment supports a flourishing industry where the convergence of advanced manufacturing capabilities and strong R&D investment propels innovation and meets the growing demand for peptide-based therapies.


Recent Developments:

  • In Jan 2024, WuXi AppTec launched two new peptide manufacturing plants in Changzhou and Taixing, China. These facilities utilize state-of-the-art digital operations and automated solvent delivery systems to enhance production efficiency and minimize errors.
  • In June 2024, Almac Group expanded its commercial manufacturing, packaging, and peptide production capacity with two new purpose-built facilities at its headquarters. This initiative is part of a comprehensive global expansion investment exceeding $500 million.
  • In November 2022, Mesa Laboratories, Inc. acquired Belyntic GmbH's peptide purification business, excluding current assets, for a transaction price not deemed material to Mesa's ongoing operations. This acquisition enhances Mesa's peptide synthesis business with a strategic addition of Belyntic's peptide purification products, complementing their portfolio with advantaged consumables.


Segmentation of Peptide CDMO (Pharmaceutical) Market-


By Scale of Operation:

  • Preclinical / Clinical
  • Commercial

By Method Used:

  • Chemical Synthesis Method
  • Non-Chemical Synthesis Method

By Applications:

  • Peptide Supplements
  • Peptide Vaccines
  • Peptides as Radio-Theranostic Agents
  • Cell Penetrating Peptides (CPPs)
  • Affinity Ligands
  • Protein Mimics

By Synthesis Types:

  • LPPS
  • SPPS
  • Mixed Phase


By Region-

North America-

  • The US
  • Canada
  • Mexico


  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe


  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa